Guadagnuolo V, Papayannidis C, Iacobucci I, et al. SIRPB1: biomarker of response to 5-azacitidine treatment in MDS and AML patients. EHA 2017, abstract E1201.
Rituximab of obinutuzumab of plus CHOP bij nieuw-gediagnostiseerd DLBCL
aug 2017 | Lymfoom